Insulin Delivery Devices Market Report 2024

This Insulin Delivery Devices market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The insulin delivery devices market size has grown strongly in recent years. It will grow from $16.38 billion in 2023 to $17.71 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the convenience and ease of use provided by insulin delivery devices, favorable reimbursement policies, the rising prevalence of obesity, an aging population, and the increasing adoption of insulin pumps.

The insulin delivery devices market size is expected to see strong growth in the next few years. It will grow to $24.32 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, rising healthcare expenditure on diabetes care, the expansion of continuous glucose monitoring systems, growing patient awareness of the benefits of automated insulin delivery devices, and an increased focus on healthcare. Key trends expected during this period include technological advancements in insulin delivery devices, the integration of digital technology with these devices, the development of artificial pancreas systems, and progress in both insulin administration and bionic technologies.

The increasing prevalence of diabetes is expected to drive the growth of the insulin delivery device market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels due to either insufficient insulin production by the pancreas or the body’s inability to effectively use insulin. The rise in diabetes cases is largely attributed to factors such as sedentary lifestyles, poor diets, and increasing obesity rates worldwide. Insulin delivery devices are essential for managing diabetes, as they allow individuals to control their blood sugar levels effectively by administering insulin in a controlled and convenient manner, thus preventing complications and promoting overall health. For example, according to the Centers for Disease Control and Prevention, a U.S.-based government agency, as of December 2022, the number of young people under 20 with type 2 diabetes in the United States could increase by nearly 700% by 2060, potentially reaching 220,000 individuals. Additionally, diagnoses of type 1 diabetes among young people could rise by as much as 65% over the same period. This growing prevalence of diabetes is fueling the expansion of the insulin delivery device market.

Leading companies in the insulin delivery device market are focusing on developing innovative products, such as insulin pumps, which provide continuous or customizable insulin delivery. Insulin pumps are programmable medical devices that deliver insulin continuously or on demand through a catheter placed under the skin. For instance, in May 2023, Beta Bionics, a U.S.-based medical technology company, received approval from the U.S. Food and Drug Administration for its iLet ACE Pump and iLet Dosing Decision Software. The iLet Bionic Pancreas system, designed for individuals aged six and older with type 1 diabetes, integrates two devices with a compatible FDA-cleared integrated continuous glucose monitor (iCGM). This system operates using an automated insulin dosing (AID) system driven by an adaptive closed-loop algorithm, which only requires the user’s body weight for setup and eliminates the need for additional insulin dosing parameters. Unlike traditional pump therapy, this system requires no manual adjustment of settings, making it easier to initiate and manage. Additionally, the iLet device introduces a meal announcement feature that simplifies mealtime insulin dosing by categorizing meals as small, medium, or large, with the algorithm learning and adapting to individual insulin needs over time.

In September 2023, Abbott, a U.S.-based healthcare company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott’s position in diabetes care by expanding its renowned FreeStyle Libre portfolio of continuous glucose monitoring technology. The move aligns with Abbott’s strategy to advance connected solutions, aiming to personalize and refine diabetes management. Bigfoot Biomedical is a U.S.-based manufacturer of insulin delivery devices.

Major companies operating in the insulin delivery devices market are Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Medtronic Plc, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, EOFlow Co. Ltd., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Xeris Pharmaceuticals Inc., Beta Bionics Inc., Zealand Pharma AS, Bigfoot Biomedical Inc., Emperra GmbH, Animas Corporation, Debiotech SA, CeQur Corporation, Aerami Therapeutics Inc., Alshifa Medical Group, AMF Medical SA, Andain Inc., Avecho Biotechnology Ltd., Apex Medical Devices.

North America was the largest region in the insulin delivery devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the insulin delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Insulin delivery devices are medical tools designed to administer insulin to individuals with diabetes. These devices are essential for managing blood glucose levels in people who are unable to produce sufficient insulin naturally. They help control blood sugar levels effectively, offering flexibility and convenience in insulin administration.

The primary types of insulin delivery devices include insulin syringes, insulin jet injectors, pen needles, reusable insulin pens, disposable insulin pens, insulin pumps, external or tethered pumps, and patch pumps. Insulin syringes, in particular, are designed for the subcutaneous injection of insulin, featuring fine, short needles and clearly marked dosage indicators to ensure precise hormone delivery. These devices are used for both type 1 and type 2 diabetes and are available through various channels, including hospital pharmacies, retail pharmacies, online sales, and diabetes clinics or centers.

The insulin delivery devices market research report is one of a series of new reports that provides insulin delivery devices market statistics, including insulin delivery devices industry global market size, regional shares, competitors with a insulin delivery devices market share, detailed insulin delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the insulin delivery devices industry. This insulin delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin delivery devices market consists of sales of insulin infusion sets, insulin reservoirs, insulin pump accessories, and insulin cartridges. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.